The company's stock was nevertheless down more than 13 percent amid investor concerns about lack of intent-to-treat analysis on two-stage fibrosis improvement and gall stone events.
The acquisition fits into a growing trend of pharma and medical device companies adding services supporting patient engagement both to quantify and improve the effectiveness of their drugs and devices and to gain additional insight from their customer base.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
mySugr Importer (English) from mySugr on Vimeo. mySugr is a diabetes app developer that’s striving to set itself apart from other direct-to-consumer mobile health companies for chronic conditions. Its apps are intended to strike a balance between relevant and important information for its users with colorful graphics and a gaming component. With a $4.8 million […]
We can now grow complex human brain tissue in a test tube. Scientists in Vienna, Austria, used a method that allows pluripotent stem cells to develop into mini-brains (i.e., cerebral organoids) that even have several distinct brain regions, according to an article in this issue of Nature. While this year has seen 3-D printed miniature […]